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Abstract: Deﬁciency in P-type ATP8B1 is a severe and clinically
highly variable hereditary disorder that is primarily characterized
by intrahepatic cholestasis. It presents either as a progressive (pro-
gressive familial intrahepatic cholestasis type 1 [PFIC1]) or intermit-
tent (benign recurrent intrahepatic cholestasis type 1 [BRIC1])
disease. ATP8B1 deﬁciency is caused by autosomal recessive
mutations in the gene encoding ATP8B1, a putative aminophospho-
lipid-translocating P-type adenosine triphosphatase. The exact path-
ogenesis of the disease is elusive, and no effective pharmacological
therapy is currently available. Here, the molecular consequences of
six distinct ATP8B1 missense mutations (p.L127P, p.G308V,
p.D454G, p.D554N, p.I661T, and p.G1040R) and one nonsense muta-
tion (p.R1164X) associated with PFIC1 and/or BRIC1 were systemat-
ically characterized. Except for the p.L127P mutation, all mutations
resulted in markedly reduced ATP8B1 protein expression, whereas
messenger RNAexpressionwasunaffected. Five out of sevenmutations
resulted in (partial) retention of ATP8B1 in the endoplasmic reticulum.
Reduced protein expression was partially restored by culturing the
cells at 30 C and by treatment with proteasomal inhibitors, which
indicates protein misfolding and subsequent proteosomal degrada-
tion. Protein misfolding was corroborated by predicting the conse-
quences of most mutations onto a homology model of ATP8B1.
Treatmentwith4-phenylbutyrate, a clinically approvedpharmacolog-Journal of Hepatology 20
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phenylbutyrate; 6-ECDCA, 6-ethyl chenodeoxycholic acid.of ATP8B1 substitutions G308V, D454G, D554N, and in particular
I661T, which is the most frequently identiﬁed mutation in BRIC1.
Conclusion: A surprisingly large proportion of ATP8B1 mutations
resulted in aberrant folding and decreased expression at the plasma
membrane. These effects were partially restored by treatment with
4-phenylbutyrate. We propose that treatment with pharmacological
chaperones may represent an effective therapeutic strategy to
ameliorate the recurrent attacks of cholestasis in patients with inter-
mittent (BRIC1) disease.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Progressive familial intrahepatic cholestasis (PFIC) refers to a het-
erogeneous group of autosomal recessive liver disorders of child-
hood in which cholestasis of hepatocellular origin often presents
in the neonatal period or ﬁrst year of life and leads to death from
liver failure at ages usually ranging from infancy to adolescence
[1]. Recent molecular and genetic studies have shown that PFIC
was related to severe mutations in canalicular transporter genes
involved in bile formation [1]. PFIC1 is caused by mutation of the
ATP8B1 gene encoding FIC1, a P-type ATPase which is a mem-
brane aminophospholipid translocator expressed in several
organs. In the liver it is essential for a proper composition of
the canalicular membrane, and thus for normal bile ﬂow [1].
PFIC2 is caused by a mutation in the ABCB11 gene encoding BSEP,
the ATP-dependent canalicular bile salt export pump [1]. PFIC3 is
caused by a mutation in the ABCB4 gene encoding MDR3, a P-gly-
coprotein of class III multidrug resistance proteins, involved in
canalicular biliary phosphatidylcholine secretion [1]. Moderate
deﬁciencies in FIC1 and BSEP may lead to a milder phenotype
with episodes of cholestasis and intractable pruritus: benign
recurrent intrahepatic cholestasis (BRIC1 and 2, respectively) [1].
Even though medical therapy such as ursodeoxycholic acid,
rifampicin, cholestyramine, and/or surgical therapy such as bili-
ary diversion might provide some symptomatic relief in PFIC1-3
patients, in the majority of cases liver transplantation (LT) is
required because of severe cholestasis and unremitting pruritus,
hepatic failure, or hepatocellular carcinoma [1,2]. So far, trans-
plantation of human hepatocytes has not proven efﬁcient and10 vol. 53 j 385–387
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gene therapy has not been initiated [1,2]. While LT is curative in
most cases, some severe complications may occur after LT. In
PFIC1 patients, severe diarrhea and progressive fatty liver disease,
as well as extradigestive symptoms, probably due to the extrahe-
patic expression of FIC1, have been described after LT [1,2]. More-
over, in PFIC2 patients, recurrence of BSEP deﬁciency after LT has
been recently described resulting from production of antibodies
by the recipient in response to an allo-immunization against
BSEP of the donor liver [1,3,4]. These speciﬁc complications of
LT highlight the need for alternative therapies such as tailored
pharmacological therapy in these diseases [1,2].
As previously described, mutations in the canalicular trans-
porters cause defective bile formation and retention of sub-
stances which are normally secreted into the bile. This may be
due to decreased transporter expression at the canalicular mem-
brane due to truncating or missense mutations that may lead to
complete absence of protein expression, or to an abnormal intra-
cellular trafﬁcking with ER retention due to protein misfolding,
respectively. Alternatively, some missense mutants, althoughHepato
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Fig. 1. Mutation speciﬁc drug therapy in PFIC/BRIC. Identiﬁcation of the mutation class
of the mutant protein (immunohistochemistry), in vitro study of the protein trafﬁcking/p
the effect of various drugs, constitute the rational to guide a mutation speciﬁc drug th
aminoglycosides, PTC124), endoplasmic reticulum associated degradation (ERAD) inhibiti
drugs (e.g. 4-PBA, curcumin), and increased gene transcription by nuclear receptor agoni
render possible, sufﬁcient expression of a functional protein at the canalicular membra
386 Journal of Hepatology 201correctly targeted at the canalicular membrane, may simply lead
to a functional defect of the protein itself. Studies at the protein
level have revealed that most ABCB11 missense mutations
responsible for PFIC2 lead to trafﬁcking impairment and
increased proteasomal degradation of the resulting mutated BSEP
[5,6]. In PFIC3 it has been shown that one missense mutation
leads to protein misfolding [7]. Such studies were lacking con-
cerning PFIC1.
In a recent paper, van der Velden et al. studied protein expres-
sion in non-hepatocellular origin cell lines (HEK293T and U2OS
cells) of human wild type FIC1 as well as 7 (6 missense, 1 non-
sense) mutants known for being responsible for PFIC1 and/or
BRIC1 [8]. A protein expression study was performed using tran-
sient transfection, and site-directed mutagenesis was performed
in plasmid constructs containing the human ATP8B1 cDNA. The
total expression level of FIC1 was decreased in all missense
mutants but one. Plasma membrane expression was decreased
in four of the missense mutants and completely absent in the
nonsense mutant. An incubation with a proteasomal degradationCanalicular membrane
cyte
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roteasomal degradation, of residual function of the mutated protein as well as of
erapy strategy. Read through premature stop codon (mainly UGA) by drugs (e.g.
on by ERAD inhibitors (e.g. MG132), correction of protein misfolding by chaperone
sts (e.g. 6-ECDCA, ﬁbrates, statins), are different approaches that could be used to
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inhibitor increased protein expression levels. Incubating at a
reduced temperature, as well as with 4-phenylbutyrate (4-PBA),
a pharmacological chaperone, increased protein expression and/
or cell surface abundance of four of the FIC1 missense mutants.
These results show that some mutations in ATP8B1 responsible
for PFIC1 and/or BRIC1 lead to signiﬁcant changes in FIC1 struc-
ture, which are responsible for protein misfolding and subse-
quent increased proteasomal degradation and/or protein
mistrafﬁcking/mislocalizing, eventually resulting in a reduction
in the plasma membrane expression level of FIC1. The authors
showed in vitro that proteasomal inhibitor and/or chaperone
drugs such as 4-PBA can increase the cell surface abundance of
some FIC1 mutants involved in PFIC1 and BRIC1. Even though
no functional data about the consequence of the mutations before
and after 4-PBA therapy are provided, these results support the
concept of chaperone drug therapy in patients affected with
PFIC1 or BRIC1. Such in vitro results are in line with previous
observations showing that 4-PBA ameliorates cell surface abun-
dance of a number of misfolded and mislocalized mutated mem-
brane proteins involved in human liver diseases. These include
some BSEP mutants identiﬁed in PFIC2 patients, cystic ﬁbrosis
transmembrane conductance regulator DF508 mutant, and some
ATP7B mutants involved in Wilson disease [9–11].
Indeed, understanding the effects of selected mutations in
these canalicular transporters at the protein level, and testing
mutation speciﬁc drugs in vitro, constitute the basis for future
in vivo personalized drug therapies for PFIC/BRIC (Fig. 1). Before
translation into the clinical setting becomes feasible, conﬁrma-
tory studies should be done, in vitro in human hepatocellular
polarized cell lines, and/or in vivo in mutant liver models. The
ultimate goal is to increase the canalicular expression level of a
functional protein just enough to reverse the deﬁcient phenotype.
A partial reversion into a milder phenotype would also be of ben-
eﬁt. In case of a nonsense mutation, read through premature stop
codons drugs (e.g. aminoglycosides, PTC124) could be used [9].
When a missense mutation is responsible for protein misfolding,
pharmacological chaperones (e.g. 4-PBA, curcumin) could
increase canalicular targeting whereas endoplasmic reticulum
associated degradation (ERAD) inhibitors (e.g. MG132) could
inhibit the subsequent proteasomal degradation [5,8,10,11].
Lastly, agonists of nuclear receptors [e.g. 6-ethyl chenodeoxycho-
lic acid (6-ECDCA), ﬁbrates, statins] could be used to increase
gene transcription of a missense mutant correctly addressed/tar-
geted at the canalicular membrane and having residual activity
[12]. These drugs could theoretically be used in combination to
increase the expression level of functional protein at the canalic-
ular membrane. Some of them, such as PTC124, 4-PBA, 6-ECDCA,
or fenoﬁbrate, are clinically approved and have already beenJournal of Hepatology 201tested, or are currently tested in human clinical trials [9,12,13].
The time to start clinical trials investigating mutation speciﬁc
drug therapy in PFIC/BRIC patients is just around the corner.
One should note that such treatment might also improve extrahe-
patic FIC1 related disease but might not abolish the risk of hepa-
tocellular carcinoma associated with such chronic hepatocellular
cholestasis, especially in BSEP deﬁciency, unless a high or full level
of correction of protein dysfunction is achieved and no cell is
already engaged in an irreversible malignant process.References
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